Stay updated on Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial

Sign up to get notified when there's something new on the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.4.3, replacing Revision: v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-11T15:25:23.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    Primary completion and study completion are now estimated for 2026-12-31, and enrollment is updated to 24 participants. Recent update dates (2026-02-13 and 2026-02-17) were added and an older date (2026-02-28) was removed.
    Difference
    0.3%
    Check dated 2026-02-18T07:46:37.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.4.2 added; the prior funding-lapse notice (v3.4.1) was removed.
    Difference
    0.4%
    Check dated 2026-02-11T10:22:23.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    Added a government funding lapse notice affecting site updates and a page revision note showing version v3.4.1, replacing the previous v3.4.0.
    Difference
    0.4%
    Check dated 2026-02-04T06:55:42.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    Added Show glossary option and a display of Last Update Submitted that Met QC Criteria, along with a Revision: v3.4.0 and a No FEAR Act Data entry. Removed Last Update Submitted that met QC Criteria, No FEAR Act data, and the older Revision: v3.3.4.
    Difference
    0.2%
    Check dated 2026-01-28T05:09:03.000Z thumbnail image
  8. Check
    62 days ago
    Change Detected
    Summary
    A minor revision update from v3.3.3 to v3.3.4 is shown; there are no apparent changes to the study details, eligibility criteria, or other content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T02:15:01.000Z thumbnail image

Stay in the know with updates to Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page.